search
Back to results

Prostate Biopsy, Transrectal vs. Transperineal: Efficacy and Complications (ProBE-PC)

Primary Purpose

Prostate Cancer, PSA, Infection

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Systematic Transrectal biopsy (TR-Bx)
Targeted Transrectal biopsy (TR-Bx)
Systematic Transperineal biopsy (TP-Bx)
Targeted Transperineal biopsy (TP-Bx)
Sponsored by
Albany Medical College
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Prostate Cancer focused on measuring Prostate biopsy, PSA, infection, bleeding

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • All patients who are scheduled to undergo prostate biopsy for suspected prostate cancer as part of their regular medical care
  • Either with or without an MRI

Exclusion Criteria:

  • Patients with no access to rectum (due to previous rectal surgery)
  • Any abnormalities of the perineal skin (e.g. infection)
  • Patients whose procedure requires sedation or general anesthesia

Sites / Locations

  • Albany Medical CollegeRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Experimental

Experimental

Arm Label

Systematic Transrectal biopsy (TR-Bx)

Targeted Transrectal biopsy (TR-Bx)

Systematic Transperineal biopsy (TP-Bx)

Targeted Transperineal biopsy (TP-Bx)

Arm Description

Ultrasound guided; needle inserted through the rectum to reach the prostate

MRI-guided; needle inserted through the rectum to reach the prostate

Ultrasound guided; needle inserted directly through the skin to reach the prostate

MRI-guided; needle inserted directly through the skin to reach the prostate

Outcomes

Primary Outcome Measures

Rate of infectious complications
Whether or not patient had an infection after the biopsy

Secondary Outcome Measures

Clinically significant cancer detection rate
The rate of grade group 2 prostate cancer detected in each study arm
Rate of Bleeding complications
The type of bleeding and its severity (blood in urine or stool)
Tolerability under local anesthesia
Pain scores; Need for additional analgesia
Patient reported urinary function measures using IPSS questionaire
International Prostate Symptoms Score (IPSS) to measure urinary function
Cost of the procedures
Differences in the actual cost of the procedures (including supplies, time)
Patient reported sexual function measures using IIEF questionaire
International Index of Erectile Function (IIEF) to measure sexual dysfunction

Full Information

First Posted
September 5, 2019
Last Updated
June 20, 2023
Sponsor
Albany Medical College
search

1. Study Identification

Unique Protocol Identification Number
NCT04081636
Brief Title
Prostate Biopsy, Transrectal vs. Transperineal: Efficacy and Complications
Acronym
ProBE-PC
Official Title
Prospective, Randomized Study Comparing Transperineal and Transrectal Prostate Biopsy Efficacy and Complications (ProBE-PC Trial)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 2, 2019 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Albany Medical College

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates the difference between 2 prostate biopsy methods, transrectal (through the rectal wall) and transperineal (through the skin) needle biopsy. Men who are in need of prostate biopsy due to clinical suspicions of prostate cancer will be randomly assigned (1:1) to either transrectal or transperineal approach. This research study will scientifically determine if one biopsy method is better than the other in reducing complications and improving cancer detection.
Detailed Description
There are two ways to take biopsy (tissue) samples from the prostate. The more commonly used method is trans-rectal needle biopsy of the prostate (TR-Bx) with a needle inserted through a probe in the rectum to reach the prostate. TR-Bx is usually performed in the office, using local anesthesia, and often using a targeted biopsy approach using MRI/ultrasound fusion technique. Trans-perineal biopsy (TP-Bx) with a needle inserted directly through the skin to reach the prostate. Typically, TP-BX is performed in the outpatient surgical setting due significant pain associated with the procedure, requiring the use anesthesia and/or sedation. TP-Bx. procedure is very uncommon in the USA and is often performed using ultrasound alone (less accurate), without the benefit of MRI guided targeted biopsy. Now, with the availability of new devices, we are able to perform both TR-Bx and TP-Bx using MRI/ultrasound fusion guided targeted approach, in the office setting, using local anesthesia alone. With the TR-Bx, there has been increasing risk of infection related complications, sepsis and hospital admissions. The newer approach of biopsy TP-Bx may cause fewer infections and may have a higher accuracy of finding cancer. Using validated questionnaires such as IIEF-6, IPSS and TRUS-BxQ, this randomized study of TR-BX and TP-Bx will address these questions: Differences in the risk of infectious complications Differences in the hemorrhagic and urinary side effects Tolerability of both techniques with local anesthesia alone Difference in the results of of MRI/US fusion targeted biopsy Differences in the overall cancer detection rate and the high-grade cancer detection rate Differences in the cost of the procedures

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer, PSA, Infection
Keywords
Prostate biopsy, PSA, infection, bleeding

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized 1:1 to either trans-rectal needle biopsy (TR-Bx) or Trans-perineal biopsy (TP-Bx) of the prostate. Both arms, either with or without MRI guided biopsy
Masking
None (Open Label)
Allocation
Randomized
Enrollment
774 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Systematic Transrectal biopsy (TR-Bx)
Arm Type
Active Comparator
Arm Description
Ultrasound guided; needle inserted through the rectum to reach the prostate
Arm Title
Targeted Transrectal biopsy (TR-Bx)
Arm Type
Active Comparator
Arm Description
MRI-guided; needle inserted through the rectum to reach the prostate
Arm Title
Systematic Transperineal biopsy (TP-Bx)
Arm Type
Experimental
Arm Description
Ultrasound guided; needle inserted directly through the skin to reach the prostate
Arm Title
Targeted Transperineal biopsy (TP-Bx)
Arm Type
Experimental
Arm Description
MRI-guided; needle inserted directly through the skin to reach the prostate
Intervention Type
Procedure
Intervention Name(s)
Systematic Transrectal biopsy (TR-Bx)
Other Intervention Name(s)
ultrasound guided
Intervention Description
Through the rectum
Intervention Type
Procedure
Intervention Name(s)
Targeted Transrectal biopsy (TR-Bx)
Other Intervention Name(s)
MRI guided
Intervention Description
Through the rectum
Intervention Type
Procedure
Intervention Name(s)
Systematic Transperineal biopsy (TP-Bx)
Other Intervention Name(s)
ultrasound guided
Intervention Description
Through the perineal skin
Intervention Type
Procedure
Intervention Name(s)
Targeted Transperineal biopsy (TP-Bx)
Other Intervention Name(s)
MRI guided
Intervention Description
Through the perineal skin
Primary Outcome Measure Information:
Title
Rate of infectious complications
Description
Whether or not patient had an infection after the biopsy
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Clinically significant cancer detection rate
Description
The rate of grade group 2 prostate cancer detected in each study arm
Time Frame
14 days
Title
Rate of Bleeding complications
Description
The type of bleeding and its severity (blood in urine or stool)
Time Frame
30 days
Title
Tolerability under local anesthesia
Description
Pain scores; Need for additional analgesia
Time Frame
30 days
Title
Patient reported urinary function measures using IPSS questionaire
Description
International Prostate Symptoms Score (IPSS) to measure urinary function
Time Frame
30 days
Title
Cost of the procedures
Description
Differences in the actual cost of the procedures (including supplies, time)
Time Frame
30 days
Title
Patient reported sexual function measures using IIEF questionaire
Description
International Index of Erectile Function (IIEF) to measure sexual dysfunction
Time Frame
30 days

10. Eligibility

Sex
Male
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients who are scheduled to undergo prostate biopsy for suspected prostate cancer as part of their regular medical care Either with or without an MRI Exclusion Criteria: Patients with no access to rectum (due to previous rectal surgery) Any abnormalities of the perineal skin (e.g. infection) Patients whose procedure requires sedation or general anesthesia
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Brenda Romeo, CCRC
Phone
518-262-8579
Email
amcurologyresearch@amc.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Badar M Mian
Email
mianb@amc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Badar M Mian, MD
Organizational Affiliation
Albany Medical College
Official's Role
Principal Investigator
Facility Information:
Facility Name
Albany Medical College
City
Albany
State/Province
New York
ZIP/Postal Code
12208
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brenda Romeo, CCRC
First Name & Middle Initial & Last Name & Degree
Hugh fisher, MD
First Name & Middle Initial & Last Name & Degree
Ashar Ata, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
30415878
Citation
Choi YH, Kang MY, Sung HH, Jeon HG, Chang Jeong B, Seo SI, Jeon SS, Kim CK, Park BK, Lee HM. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis. Clin Genitourin Cancer. 2019 Feb;17(1):e19-e25. doi: 10.1016/j.clgc.2018.09.007. Epub 2018 Sep 13.
Results Reference
background
PubMed Identifier
29552975
Citation
Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budaus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18.
Results Reference
background
PubMed Identifier
28336078
Citation
Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouviere O. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol. 2017 Aug;72(2):250-266. doi: 10.1016/j.eururo.2017.02.026. Epub 2017 Mar 21.
Results Reference
background
PubMed Identifier
30271182
Citation
Wu YP, Li XD, Ke ZB, Chen SH, Chen PZ, Wei Y, Huang JB, Sun XL, Xue XY, Zheng QS, Xu N. Risk factors for infectious complications following transrectal ultrasound-guided prostate biopsy. Infect Drug Resist. 2018 Sep 17;11:1491-1497. doi: 10.2147/IDR.S171162. eCollection 2018.
Results Reference
background
PubMed Identifier
27543165
Citation
Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, Weidner W, Loeb S. Complications After Systematic, Random, and Image-guided Prostate Biopsy. Eur Urol. 2017 Mar;71(3):353-365. doi: 10.1016/j.eururo.2016.08.004. Epub 2016 Aug 17.
Results Reference
background
PubMed Identifier
28363690
Citation
Liss MA, Ehdaie B, Loeb S, Meng MV, Raman JD, Spears V, Stroup SP. An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy. J Urol. 2017 Aug;198(2):329-334. doi: 10.1016/j.juro.2017.01.103. Epub 2017 Mar 29.
Results Reference
background
PubMed Identifier
27774521
Citation
Saade EA, Suwantarat N, Zabarsky TF, Wilson B, Donskey CJ. Fluoroquinolone-Resistant Escherichia coli Infections After Transrectal Biopsy of the Prostate in the Veterans Affairs Healthcare System. Pathog Immun. 2016;1(2):243-257. doi: 10.20411/pai.v1i2.123.
Results Reference
background
PubMed Identifier
30760274
Citation
Xiang J, Yan H, Li J, Wang X, Chen H, Zheng X. Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis. World J Surg Oncol. 2019 Feb 13;17(1):31. doi: 10.1186/s12957-019-1573-0.
Results Reference
background
PubMed Identifier
29942197
Citation
Skouteris VM, Crawford ED, Mouraviev V, Arangua P, Metsinis MP, Skouteris M, Zacharopoulos G, Stone NN. Transrectal Ultrasound-guided Versus Transperineal Mapping Prostate Biopsy: Complication Comparison. Rev Urol. 2018;20(1):19-25. doi: 10.3909/riu0785.
Results Reference
background
PubMed Identifier
28007492
Citation
Roberts MJ, Bennett HY, Harris PN, Holmes M, Grummet J, Naber K, Wagenlehner FME. Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. Urology. 2017 Jun;104:11-21. doi: 10.1016/j.urology.2016.12.011. Epub 2016 Dec 19.
Results Reference
background
PubMed Identifier
29988098
Citation
Altok M, Kim B, Patel BB, Shih YT, Ward JF, McRae SE, Chapin BF, Pisters LL, Pettaway CA, Kim J, Demirel HC, Davis JW. Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis. 2018 Nov;21(4):524-532. doi: 10.1038/s41391-018-0056-7. Epub 2018 Jul 9.
Results Reference
background
PubMed Identifier
30835607
Citation
Stefanova V, Buckley R, Flax S, Spevack L, Hajek D, Tunis A, Lai E, Loblaw A; Collaborators. Transperineal Prostate Biopsies Using Local Anesthesia: Experience with 1,287 Patients. Prostate Cancer Detection Rate, Complications and Patient Tolerability. J Urol. 2019 Jun;201(6):1121-1126. doi: 10.1097/JU.0000000000000156.
Results Reference
background
PubMed Identifier
29409845
Citation
Meyer AR, Joice GA, Schwen ZR, Partin AW, Allaf ME, Gorin MA. Initial Experience Performing In-office Ultrasound-guided Transperineal Prostate Biopsy Under Local Anesthesia Using the PrecisionPoint Transperineal Access System. Urology. 2018 May;115:8-13. doi: 10.1016/j.urology.2018.01.021. Epub 2018 Feb 1.
Results Reference
background

Learn more about this trial

Prostate Biopsy, Transrectal vs. Transperineal: Efficacy and Complications

We'll reach out to this number within 24 hrs